Does Bevacizumab Cause Delayed Thromboembolism? Two Cases

Abstract

Cancer patients are at increased risk of venous thromboembolism (VTE) and this risk may be further increased due to several other factors including chemotherapeutic drugs. Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that has been reported to cause arterial and venous thrombosis during the treatment period. We present two cases of venous thrombosis occurring several weeks after stopping bevacizumab, raising the question of a delayed adverse drug effect due to the long half -life of the drug and immune complex formation.




J Med Cases. 2013;4(10):649-651
doi: https://doi.org/10.4021/jmc1464w